EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS G12C Inhibitors in Nonsmall Cell Lung Cancer

Zehao Pan, Yuxian Qian, Yajing Wang, Te Zhang, Xuming Song, Hanling Ding, Rutao Li, Yijian Zhang, Zi Wang, Hui Wang, Wenjie Xia, Lei Wei und 3 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Zehao Pan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Researc…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Killer Cells, Natural, Proto-Oncogene Proteins p21(ras), Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Province Capability Improvement through Project Science, Technology and Education, Jiangsu Provincial Medical Key Laboratory, National Natural Science Foundation of China, Jiangsu Provincial Medical Innovation Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS G12C inhibitors exhibit conspicuous clinical response in KRAS G12C ‐mutant lung cancer, yet adaptive resistance, the rapid onset of intrinsic resistance, dampens their therapeutic success. Rational combination strategies could tackle this challenging problem. A high‐throughput screening of a pharmacological library with 423 compounds revealed that napabucasin, a signal transducer and activator of transcription 3 (STAT3) inhibitor, synergistically potentiated the growth inhibition effect of the KRAS G12C inhibitor sotorasib in sensitive and resistant KRAS G12C NSCLC cell lines. Functional assays further revealed that the coordinated targeting of KRAS with STAT3 improved the inhibitory effect on tumor growth and augmented the infiltration and activation of natural killer (NK) cells within the tumor microenvironment. Mechanistically, KRAS G12C inhibition induced compensatory activation of STAT3, contingent on concomitant suppression of downstream ERK signaling, abrogated by napabucasin. Moreover, we unveiled and verified the binding site of phosphorylated STAT3 at the HLA‐B promoter, an inhibitor ligand for NK cells. Our study dissected an unknown mechanism of adaptive resistance to KRAS G12C inhibitors, with the STAT3 activation sustaining the regrowth of tumor cells under KRAS inhibition and up‐regulating HLA‐B transcription to dampen the cytotoxicity of infiltrated NK cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorKiller Cells, NaturalProto-Oncogene Proteins p21(ras)Lung NeoplasmsDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungHumansCell Line, TumorAnimalsMiceBenzofuransNaphthoquinonesXenograft Model Antitumor AssaysTumor MicroenvironmentMutationCytotoxicity, Immunologic

Stichwörter der Autor:innen

KRASG12CNK cellsSTAT3Sotorasibadaptive resistance

Substanzen

STAT3 Transcription FactorProto-Oncogene Proteins p21(ras)KRAS protein, humanSTAT3 protein, humannapabucasinBenzofuransNaphthoquinones

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P. R. China.
  • Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, P. R. China.
  • The Fourth Clinical College of Nanjing Medical University, Nanjing, P. R. China.
  • Department of Pathology, Jiangsu Cancer Hospital, Nanjing, P. R. China.
  • Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, P. R. China.
  • Department of Colorectal Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, P. R. China.

ORCID-Profile: Lin Xu, Feng Jiang

Förderung

  • Jiangsu Province Capability Improvement through Project Science, Technology and Education, Jiangsu Provincial Medical Key Laboratory
  • National Natural Science Foundation of China
  • Jiangsu Provincial Medical Innovation Center

Zitieren

APA

Pan, Z., Qian, Y., Wang, Y., Zhang, T., Song, X., Ding, H., Li, R., Zhang, Y., Wang, Z., Wang, H., Xia, W., Wei, L., Xu, L., Dong, G., & Jiang, F. (2025). STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS G12C Inhibitors in Nonsmall Cell Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70017

Vancouver

Pan Z, Qian Y, Wang Y, Zhang T, Song X, Ding H, et al. STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS G12C Inhibitors in Nonsmall Cell Lung Cancer. Cancer Science. 2025. doi:10.1111/cas.70017

BibTeX
@article{Pan2025,
  author = {Pan, Zehao and Qian, Yuxian and Wang, Yajing and Zhang, Te and Song, Xuming and Ding, Hanling and Li, Rutao and Zhang, Yijian and Wang, Zi and Wang, Hui and Xia, Wenjie and Wei, Lei and Xu, Lin and Dong, Gaochao and Jiang, Feng},
  title = {STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS G12C Inhibitors in Nonsmall Cell Lung Cancer},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70017}
}
Kostenlos starten →